Crescent Biopharma Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Crescent Biopharma Inc 's ROA in the second quarter of 2026?
Crescent Biopharma Inc recorded a cumulative net loss of $-94 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -49.38%.

However, within the Healthcare sector 257 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 2903 to 2934.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	16.1 %	773.11 %	583.87 %	780.8 %	544.67 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-94	-93	-85	-79	-65
Return On Assets (TTM)	-49.38 %	-50.59 %	-60.73 %	-89.82 %	-111.88 %
CBIO's Total Ranking	# 2934	# 2903	# 4306	#	#
Total Assets (TTM) in million	183	199	240	138	157
Seq. Total Assets Change	-8.22 %	-17.13 %	73.79 %	-12.17 %	590.23 %
Seq. Net Income Change	-	-	-	-	-

CBIO's 5 Years Annual ROA >> Back to CBIO Management Effectiveness >> Compare CBIO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 88
Sector	# 258
Overall	# 2941

Return On Assets Statistics
High	Average	Low
0.11 %	-33.05 %	-81.55 %
(Dec 31 2025)		(Sep 30 2025)

Financial Statements
Crescent Biopharma Inc 's Assets	$ 183 million	CBIO's Balance sheet
Crescent Biopharma Inc 's Income	$ -23 million	Quarterly CBIO's Income Statement
CBIO's Income by Division		See CBIO's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	2066.47 %	-75.52 %	-12.53 %	-45.08 %	-33.95 %
Total Assets in million	240	11	45	52	94
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-154	0	0	0	0
Annual Return On Assets	-64.06 %	0 %	0 %	0 %	0 %

CBIO's 5 Years Annual ROA >> Back to CBIO Management Effectiveness >> Compare CBIO ROA to its Competitors

More Return On Assets Ratios
CBIO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CBIO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CBIO's Competitors
Subscribers only: Roa for Crescent Biopharma Inc 's Suppliers
Subscribers only: Return On Assets for CBIO's Customers

You may also want to know
CBIO's Roi	CBIO's Inventory Turnover Ratio	CBIO's Growth Rates	CBIO's Dividend Comparisons
	CBIO's Profitability Ratios	CBIO's Asset Turnover Ratio	CBIO's Dividend Growth
CBIO's Roe	CBIO's Valuation Ratios	CBIO's Financial Strength Ratios	CBIO's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T18:18:55+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.